Role of vandetanib in the management of medullary thyroid cancer
Maryse Brassard1*, Geneviève Rondeau2* 1Endocrinology Service, Department of Medicine, Centre Hospitalier Universitaire Affilié (CHA), Laval University, Quebec, Canada; 2Endocrinology Service, Department of Medicine, Centre Hospitalier de l'Universit&...
Guardado en:
Autores principales: | Rondeau G, Brassard M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a1cb82278914d66825eb5c87a2725f9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
por: Jaclyn Flanigan, et al.
Publicado: (2010) -
Principles of medullary thyroid cancer staging according to AJCC TNM 8th edition
por: O.R Duda, et al.
Publicado: (2021) -
Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez CA, et al.
Publicado: (2012) -
Somatic Mutations in Exons 10, 11, and 16 of the RET Protooncogene in Medullary Thyroid Carcinoma Patients
por: Elham Shakiba, et al.
Publicado: (2020) -
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic N, et al.
Publicado: (2014)